3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Sarcoma
1
Neuroectodermal Tumors
1
Nervous System Diseases
1
Neoplasms, Neuroepithelial
1
Neoplasms, Nerve Tissue
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Histologic Type
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Brain Neoplasms
1
Interventions
Pemetrexed
5
ponatinib
4
pembrolizumab
4
Carboplatin
4
Cisplatin
3
130-nm albumin-bound paclitaxel
3
tetulomab tetraxetan lu-177
2
pralsetinib
2
osimertinib
2
napabucasin
2
fludarabine
2
ficlatuzumab
2
entinostat
2
durvalumab
2
atezolizumab
2
Rituximab
2
Paclitaxel
2
Lutetium
2
Irinotecan
2
Immunotherapy
2
Imatinib Mesylate
2
Gemcitabine
2
Doxorubicin
2
Dexamethasone
2
Cyclophosphamide
2
Bortezomib
2
Bevacizumab
2
vorasidenib
1
siltuximab
1
ruxolitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Neoplasms by Histologic Type
×
Interferon-gamma
×
Clear all
NCT02197169
2018-07-16
TARGET-I
DNAtrix, Inc.
Phase 1
Completed
37 enrolled